** Contract research firm Charles River Laboratories' CRL.N shares fall 11.1% to $169.01 premarket
** Company forecasts 2025 revenue will decline organically in a similar range as estimated in 2024
** Charles River in November forecast full-year 2024 revenue to decrease 2% to 3%, versus previous expectations of it falling 2.5% to 4.5%
** Company says lower commercial contract drug manufacturing revenue is expected to "reduce consolidated revenue growth by approximately 1% in 2025"
** Charles River says a cell therapy client notified CRL that it would terminate its commercial agreement with the company "to utilize another long-time CDMO partner"
** Company adds that cell and gene therapy client demand "is not as robust as at the time of acquisition, but attractive, long-term growth opportunities exist for its CDMO business"
** Stock fell 21.9% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。